N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine

Repeated dose toxicity: oral

Administrative data

Endpoint:

repeated dose toxicity: oral

Remarks:

other: not available

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1987

Reliability:

1 (reliable without restriction)

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1987

Materials and methods

Test guideline

Qualifier:

no guideline available

Principles of method if other than guideline:

Guideline not available

GLP compliance:

not specified

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine

EC Number:

401-990-0

EC Name:

N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine

Cas Number:

106990-43-6

Molecular formula:

C132H250N32

IUPAC Name:

N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine

Constituent 2

Reference substance name:

N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino) triazin-2-yl)-4,7-diazadecane-1,10-diamine

IUPAC Name:

N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino) triazin-2-yl)-4,7-diazadecane-1,10-diamine

Test material form:

solid: particulate/powder

Remarks:

migrated information: powder

Test animals

Species:

rat

Strain:

other: Albino rat

Sex:

male/female

Administration / exposure

Route of administration:

oral: unspecified

Details on oral exposure:

Method of administration: diet

Duration of treatment / exposure:

Test duration: 90 days

No. of animals per sex per dose:

Male: 10 animals at 0 mg/kg bw/day
Male: 10 animals at 9.7 mg/kg bw/day
Male: 10 animals at 47.9 mg/kg bw/day
Male: 10 animals at 201 mg/kg bw/day
Male: 10 animals at 826 mg/kg bw/day

Female: 10 animals at 0 mg/kg bw/day
Female: 10 animals at 9.92 mg/kg bw/day
Female: 10 animals at 50.4 mg/kg bw/day
Female: 10 animals at 210 mg/kg bw/day
Female: 10 animals at 817 mg/kg bw/day

Results and discussion

Results of examinations

Details on results:

Clinical observation:
Dose-related reduction of mean body weight and food consumption at 12000 and 3000 ppm.
Water cosumption decreases at 12000 ppm.

Laboratory findings:
At 12000 ppm hypocromic microcytic anemia. At 12000, 3000 and 800 ppm dose-related leucocytosis with neutrophilia and relative lymphopenia. At 12000 ppm decrease in plasma glucose, cholesterol and plasma protein; dose-related decrease in plasma albumin at 12000 and 3000 ppm.
At 12000 ppm increases in plasma electrolytes, ASAT and alcaline phosphatase; ASAT increased in females at 3000 and 800 ppm too. Bilirubinuria at 12000 ppm.

Effects in organs:
Increase of liver relative weight in females at 12000 ppm and of spleen relative weight in females at 3000 and 12000 ppm. Enlarges mesenteric lymphonodes at 800, 3000 and 12000 ppm. Two/20 rats at 12000 ppm had mottled liver.

Marked, widespread presence of foam macrophages, expecially in the mucosa of small intestine and in the mesenteric lymphnodes. The change was evident form 150 ppm exposure upwards, and its intesity was dose-related.
At 800, 3000 and 12000 ppm necrotizing, inflammatory and cystic changes in mesenteric lymph nodes, peritoneal inflammation, and inflammatory infiltrates in liver (1/20 at 800 ppm) were also present.

Effect levels

Dose descriptor:

NOEL

Effect level:

< 9.7 mg/kg bw/day (nominal)

Basis for effect level:

other: original NCD unit is mg/kg/day

Target system / organ toxicity

Critical effects observed:

not specified

Applicant's summary and conclusion

Conclusions:

The substance is not classified.